Home › Upcoming votes › Akari Therapeutics Plc
This meeting took place on October 28, 2026. Akari Therapeutics Plc reported the official results on Form 8-K, filed October 30, 2026 (read it on EDGAR); they are listed below.
Read the proxy statement on EDGAR
Ballot: see the proxy statement. The items on this ballot could not be read from the filing with enough confidence to list them here. Read the proxy statement.
From Akari Therapeutics Plc’s Form 8-K, filed December 16, 2025, for the meeting held December 15, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| To approve, in accordance with Nasdaq Listing Rule 5635(d), the exercisability of certain warrants and the issuance of the ordinary shares u | 99.5% | — |
| That, in accordance with section 618 of the U.K. Companies Act 2006 (the "Companies Act"), and subject to and conditional upon the passing o | 99.7% | — |
| That subject to and conditional upon the passing of Resolutions 2, 4, 5 and 6, and in accordance with section 551 of the Companies Act, the | 98% | — |
| That subject to and conditional upon the passing of Resolutions 2, 3, 5 and 6, the share buyback contract in the form produced to the Meetin | 99.3% | — |
| That subject to and conditional upon the passing of Resolutions 2, 3, 4, and 6, in accordance with section 570 of the Companies Act, the dir | 98% | — |
| That subject to and conditional upon the passing of Resolutions 2, 3, 4 and 5, the draft New Articles be adopted as the articles of associat | 99.2% | — |
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| To generally and unconditionally authorize an increase in the number of shares available for the grant of awards under the 2023 Plan by 144, | 98% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.